WuXi Pharma’s Combination with Charles River

On April 26, 2010, Cravath advised Shanghai, China-based WuXi PharmaTech (Cayman) Inc. in its proposed agreement to combine with Charles River Laboratories International, Inc. in a cash and stock transaction valued at $1.6 billion. The transaction, which was terminated on July 29, 2010, would have been among the largest acquisitions of a China-based company by a U.S. acquirer.

The Cravath team included partner Faiza J. Saeed and associates Dean M. Mades, Craig Smith and Richard N. Luft on corporate matters; partner Eric W. Hilfers and associate Jared R. Whalen on executive compensation and benefits matters; practice area attorney Thomas C. Viles and associate Mark L. Silverstein on antitrust matters; and partner Andrew W. Needham on tax matters.